IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Terrance P. SNUTCH et al.

Application No.: 10/821,389

Filing Date: April 9, 2004

For: CALCIUM CHANNEL INHIBITORS

COMPRISING BENZHYDRIL SPACED

FROM PIPERAZINE

Examiner: B. Packard

Group Art Unit: 1612

Confirmation No.: 1599

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & §1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	With the application; accordingly, no fee or separate requirements are required.	
	Before the mailing of a first Office Action after the filing of a Request for Continued	
	Exami	nation under 37 C.F.R. § 1.114. However, if applicable, a certification under 37
	C.F.R.	§ 1.97 (e)(1) has been provided.
	Within three months of the application filing date or before mailing of a first Office Action	
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applica	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
After receipt of		receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.	
	\boxtimes	A fee is required. Accordingly, a fee is provided via EFS-Web.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the	
	Issue Fee.	
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		Form (PTO/SB/17) is attached to this submission.)

This Information Disclosure Statement is submitted:

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including

extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>381092000624</u>.

Dated: May 20, 2009 Respectfully submitted,

By: /Kate H. Murashige/ Kate H. Murashige Registration No.: 29,959 MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040 (858) 720-5112

> Serial No. 10/821,389 Docket No. 381092000624